SCHEMBL2697700

SCHEMBL2697700

CN(C)CC(=O)N1CCc2nc(C(C)(C)C)sc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
TLR9 Q9NR96 3/20 0.44
TLR8 Q9NR97 3/20 0.44
TLR7 Q9NYK1 3/20 0.44
KDM4E B2RXH2 1/20 0.41
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
DPP7 Q9UHL4 2/20 0.41
PRKCI P41743 1/20 0.38
MAPK10 P53779 1/20 0.38
P2RX3 P56373 1/20 0.36
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
KCNH2 Q12809 1/20 0.35
PI4KB Q9UBF8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16285307 0.86 NPC1 (0.47) GRM5NPC1RAB9AKDM4EDPP4
SCHEMBL16285303 0.86 NPC1 (0.59) GRM5NPC1RAB9AKDM4EDPP4
SCHEMBL13494214 0.83 DPP4 (0.49) GRM5NPC1RAB9ATLR9TLR8
SCHEMBL12340949 0.83 GRM5 (0.39) GRM5NPC1RAB9AKDM4EDPP4
SCHEMBL2699242 0.81 GRM5 (0.53) GRM5NPC1RAB9ATLR8TLR7
SCHEMBL13494262 0.80 TLR9 (0.50) GRM5NPC1RAB9ATLR9TLR8
SCHEMBL2700056 0.79 RXFP1 (0.46) GRM5NPC1RAB9AKDM4E
SCHEMBL20368922 0.78 GRM5 (0.42) GRM5NPC1RAB9ADPP4DPP8
SCHEMBL9964552 0.78 GRAMD1A (0.44) GRM5NPC1RAB9ADPP4DPP8
SCHEMBL21845385 0.77 GRM5 (0.45) GRM5NPC1RAB9ATLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 GRM5 1235/4885NPC1 277/4885RAB9A 2514/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 GRM5 1235/4885NPC1 277/4885RAB9A 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.